ACIP, Hep B Vaccine, FDA Drug Vouchers: Morning Rounds
- Okay, here's a summary of the provided STAT News article excerpts, broken down by topic:
- * NIH Investment: The National Institutes of Health (NIH) is investing $87 million in a new center to standardize organoid research.
- * Breakthrough Drug: Gilead Sciences has developed Yeztugo, a twice-yearly injectable drug highly effective in preventing HIV.
Okay, here’s a summary of the provided STAT News article excerpts, broken down by topic:
1. Organoid Research & Animal testing
* NIH Investment: The National Institutes of Health (NIH) is investing $87 million in a new center to standardize organoid research.
* Goal: This is part of a broader effort to reduce reliance on animal models (mice, primates, etc.) in research, fulfilling a previous pledge.
* Challenges: The rapid progress in organoid technology isn’t without ethical and practical hurdles (as detailed in a linked STAT article).
2. HIV Prevention – Yeztugo
* Breakthrough Drug: Gilead Sciences has developed Yeztugo, a twice-yearly injectable drug highly effective in preventing HIV.
* Cost Concerns: The current price tag of $28,000 (before rebates/discounts) is a major barrier to access, notably in the U.S. and globally.
* Potential for Affordability: A pharmacology professor suggests a generic version could potentially bring the cost down to as low as $25 per dose, enabling widespread eradication efforts.
* Gilead’s Plans: Gilead aims to have the drug accessible to 90% of the target population by June 2026.
3. Hepatitis B Vaccine Birth Dose
* Review Initiated: The vaccine Integrity Project at the University of Minnesota is conducting an independent review of the scientific evidence supporting the practice of administering the hepatitis B vaccine at birth.
* Political Pressure: This review is happening amidst pressure from supporters of Health Secretary Robert F. Kennedy, Jr. to eliminate or delay the birth dose.
* ACIP Skepticism: The CDC’s Advisory Committee on Immunization Practices (ACIP) expressed a need for more information regarding the rationale and safety of the birth dose in September,and ultimately postponed a vote.
* Unique Timing: The hepatitis B vaccine is unique in being administered at just one month old, unlike othre vaccines.
* Importance of Protection: The article emphasizes the importance of protecting babies from hepatitis B.
Let me know if you’d like me to elaborate on any of these points or analyze the article further!